Sitero Acquires Clario's eClinical Technology Suite
Sitero has announced its recent acquisition of a technology suite designed to manage the end-to-end clinical trial lifecycle. The newly acquired eClinical technology suite, formerly of Clario, will be integrated with Sitero's existing Mentor platform with plans to invest in AI to further streamline the clinical trial process. This combined suite offers tools designed to enhance efficiency, accuracy, and quality of data across the site, CRO, and sponsor lifecycle of clinical trials.
Key components of the technology platform include:
- Electronic Data Capture (EDC) and System
- Randomization and Trial Supply Management (RTSM)
- Clinical Trial Management System (CTMS)
- eTMF
- eConsent
- Site and Patient Payments
The Clario eClinical product suite will be rebranded and integrated into the Sitero Mentor platform. Sitero Mentor will continue to support the existing Clario customer base while further developing clinical solutions for new customers as well.
Reference
Sitero Acquires Clario's eClinical Technology Suite to Enhance Clinical Trial Delivery. (2023, August 1). Cision PR Newswire.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
